Fig. 3
From: 2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo
2,6-DMBQ strongly reduces the mTOR signaling pathway. a Effect of 2,6-DMBQ on EGF-induced kinase signaling in JB6 cells. Serum-starved (0.1% FBS; 24 h) cells were treated with different doses of 2,6-DMBQ for 2 h followed by treatment with EGF for 30 min. b Effect of 2,6-DMBQ on kinase signaling in gastric cancer cells. Cells were treated with 2,6-DMBQ and then various signaling proteins were examined by Western blotting. For a and b, band density was measured using the Image J (NIH) software program. All results of Western blotting are shown as mean values ± S.D. for 3 independent experiments. c Effect of 2,6-DMBQ on mTOR kinase activity. mTOR kinase activity was assessed by an in vitro kinase assay using active mTOR and inactive p70S6K proteins. mTOR inhibitor AZD8055 was used as a positive control. For c, data are shown as means ± S.D. of triplicate values from 3 independent experiments and the asterisk (*) indicates a significant (p < 0.05) difference